"Medically necessary" is often a four-letter word for patients.

We are unable to accept referrals or any form of insurance, including Medicare, Medicaid and CareSource. Medication management cannot be the sole reason for a visit. We regret the inconvenience.

Patients view prior authorization as the biggest burden in navigating the healthcare system, according to a new KFF poll. | Patients view prior authorization as the biggest burden in navigating the ...

Massachusetts insurance regulators unveiled sweeping prior authorization reforms that would scrap pre-approval requirements for "many routine and essential" health care services, Gov. Maura Healey ...

The paperwork burden of prior authorization keeps climbing, and for some ASCs, the only way through is to treat it like a daily fight. Elisa Auguste, administrator at East Setauket, N.Y.-based ...

Abridge has teamed its AI platform for clinical conversations with Availity’s digital platform that connects payers and providers to enable payer determination during a patient visit. The ...

A KFF analysis released today found that Medicare Advantage insurers made nearly 53 million prior authorization determinations in 2024, an increase from 49.8 million in 2023. The report found that MA ...

The Centers for Medicare and Medicaid Services (CMS) has implemented prior authorization requirements for certain traditional ...

CVS Health cuts prior authorizations, speeding approvals and expanding biosimilar use to reduce costs and improve patient access.

Health and immunization records submitted to or generated by Student Health Services are held on file for 7 years from the date of submission. Consent is required from students 18 years old and over, ...

Blue Shield is designing a centralized, machine-readable policy repository to enhance policy digitization and automation, speeding up prior authorization decisions. The organization has partnered with ...

The FDA has approved Incyte's Opzelura cream for atopic dermatitis, commonly called eczema, becoming the first and only topical JAK inhibitor registered in the US. Opzelura (ruxolitinib) – which has ...